Evidence map›Paper›PMID 29151979›Full record

ArticleJournal of Cancer2017

Effects of Triple Effective RNA (teRNA) on the Inhibition of Hepatocellular Carcinoma Cells.

Yuwen Xue, Tiejun Li, Shuyan Liu, York Yuanyuan Zhu, Guilan Wang, Luyu Fu, Li Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Yuwen XueDepartment of Pathological Anatomy, Nantong University, Nantong, China.
Tiejun LiSmall RNA Technology and Application Institute, Nantong University, Nantong, China.
Shuyan LiuDepartment of Pathological Anatomy, Nantong University, Nantong, China.
York Yuanyuan ZhuSmall RNA Technology and Application Institute, Nantong University, Nantong, China.
Guilan WangDepartment of Pathological Anatomy, Nantong University, Nantong, China.
Luyu FuDepartment of Pathological Anatomy, Nantong University, Nantong, China.
Li ChenDepartment of Pathological Anatomy, Nantong University, Nantong, China.
Nantong University · CNInstitute of Marine Biotechnology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The occurrence and development of hepatocellular carcinoma (HCC) is a complicate process involved in genetic mutation and epigenetic regulation. Successful HCC therapy needs multi-targets be involved. The aim of this study was to provide a triple effective RNA (teRNA) which composed of the specific siRNAs targeting NET-1 and VEGF and dsRNA activating TLR3, and explored its anti-HCC roles and mechanism. Real-time quantitative PCR (RT-qPCR), Western blot, immunofluorescence staining, MTT, Annexin V-FITC flow cytometry, Transwell and

Indexed as

hepatocellular carcinomaNET-1siRNAsliRNAteRNA.TLR3VEGF

Identifiers

PMID29151979
PMCPMC5688945
OpenAlexW2766375147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.